CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNSP CNS Pharmaceuticals, Inc.

Post-Mkt 05-22 16:42:38 EDT

5.42

+0.37

+7.33%

盘后5.27

-0.15-2.73%

16:33 EDT

High5.42	Low5.07	Vol22.99K
Open5.07	D1 Closing5.05	Amplitude6.93%
Mkt Cap7.92M	Tradable Cap7.34M	Total Shares1.46M
T/O121.19K	T/O Rate1.70%	Tradable Shares1.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNSP","market":"US","secType":"STK","nameCN":"CNS Pharmaceuticals, Inc.","latestPrice":5.42,"timestamp":1779480000000,"preClose":5.05,"halted":0,"volume":22993,"hourTrading":{"tag":"盘后","latestPrice":5.2721,"preClose":5.42,"latestTime":"16:33 EDT","volume":266,"amount":1440.7324484,"timestamp":1779481987562,"change":-0.1479,"changeRate":-0.027288,"amplitude":0.027288},"delay":0,"changeRate":0.07326732673267329,"floatShares":1354600,"shares":1461399,"eps":-29.672573,"marketStatus":"Post-Mkt","change":0.37,"latestTime":"05-22 16:42:38 EDT","open":5.07,"high":5.42,"low":5.07,"amount":121193.619756,"amplitude":0.069307,"askPrice":5.42,"askSize":20,"bidPrice":4.81,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-29.672573,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779494400000},"marketStatusCode":4,"adr":0,"listingDate":1573189200000,"exchange":"NASDAQ","adjPreClose":5.05,"preHourTrading":{"tag":"盘前","latestPrice":5.25,"preClose":5.05,"latestTime":"08:44 EDT","volume":770,"amount":4065.2442599999995,"timestamp":1779453859778,"change":0.2,"changeRate":0.039604,"amplitude":0.092475},"postHourTrading":{"tag":"盘后","latestPrice":5.2721,"preClose":5.42,"latestTime":"16:33 EDT","volume":266,"amount":1440.7324484,"timestamp":1779481987562,"change":-0.1479,"changeRate":-0.027288,"amplitude":0.027288},"volumeRatio":0.701592},"requestUrl":"/m/hq/s/CNSP/wiki","defaultTab":"wiki","newsList":[{"id":"2636847030","title":"CNS Pharma director Faith L. Charles buys 7,100 shares for $34,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847030","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636847030?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:04","pubTimestamp":1779282248,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals director Faith L. Charles bought 7,100 common shares in an open-market purchase priced at USD 4.79 per share.Her direct holding rose to 7,100 shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL4lN1dh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CNS Pharma director Faith L. Charles buys 7,100 shares for $34,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867626","title":"CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867626","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867626?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:32","pubTimestamp":1779226368,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals  on Tuesday filed a registration statement covering the resale of up to 9.79 million shares by selling stockholders.The resale includes 650,000 common shares and 9.14 million shares issuable upon exercise of prefunded warrants with a $0.001 exercise price and no expiration date.The company said it will not receive proceeds from the sales.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CNS","CNSP","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636862444","title":"CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2636862444","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636862444?lang=en_us&edition=fundamental","pubTime":"2026-05-20 05:01","pubTimestamp":1779224470,"startTime":"0","endTime":"0","summary":"16:57 EDT CNS Pharmaceuticals (CNSP) files to sell 9.79M shares of common stock for holders Published first on TheFly – the ultimate source for rea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-files-to-sell-9-79m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-files-to-sell-9-79m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNS","BK4135","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721251","title":"CNS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721251","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721251?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:51","pubTimestamp":1778795463,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings SummaryCNS Pharmaceuticals Inc CNSP.OQ reported a quarterly adjusted loss of $7.30 per share for the quarter ended Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635714712","title":"CNS Pharmaceuticals Q1 net loss widens to $4.94 million from year-ago quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2635714712","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635714712?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:56","pubTimestamp":1778759777,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals posted a net loss of $4.94 million for the quarter ended March 31, 2026, widening from $4.3 million a year earlier.Research and development expense rose to $3.54 million from $3.24 million, on higher professional expenses, headcount costs, drug manufacturing tied to TPI 287, and other items.General and administrative expense climbed to $1.43 million from $1.1 million, driven by higher legal and professional fees and insurance costs.Cash totaled $2.95 million at March 31, 2026, with a working capital deficit of $504,000.Strategy update in March pivoted focus toward developing therapies for serious diseases, including exploring out-licensing opportunities for legacy assets TPI 287 and Berubicin.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLbtMYKn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634375762","title":"CNS Pharmaceuticals Inc  expected to post a loss of $5.37 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634375762","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634375762?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:12","pubTimestamp":1778530324,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc  expected to post a loss of $5.37 a share - Earnings Preview CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to  report resultson May 13 (estimated) for the period ending Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633746137","title":"What's Going On With CNS Pharmaceuticals Stock On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2633746137","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633746137?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:51","pubTimestamp":1778075460,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals plans a pivot to an acquisition-led strategy, capital raise, and technicals signal momentum with caution.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/05/06/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/05/06/Medical-Research-And-Development-Center-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/05/52323068/whats-going-on-with-cns-pharmaceuticals-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/05/52323068/whats-going-on-with-cns-pharmaceuticals-stock-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SMA","BK4007","BK4135","CNS","BK4217","CNSP","RSI","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633508479","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2633508479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633508479?lang=en_us&edition=fundamental","pubTime":"2026-05-05 01:59","pubTimestamp":1777917556,"startTime":"0","endTime":"0","summary":"Celcuity  reported late Friday positive topline results from a cohort of its phase 3 Viktoria-1 trial, with the study meeting its primary endpoint and showing a clinically meaningful improvement in progression-free survival.The study evaluated gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer who had progressed after a CDK4/6 inhibitor and an aromatase inhibitor.Shares jumped more than 16%, with intraday trading volume at over 2.5 million from a daily average of roughly 737,000.CNS Pharmaceuticals  shares surged 268% amid heavy trading after the company said Monday it signed deals for a private placement financing likely to generate roughly $22.5 million.Intraday trading volume catapulted to over 78.4 million shares from a daily average of about 32,000.American Express Global Business Travel, which is operated by Global Business Travel Group , said Monday it has entered into a definitive agreemen","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","GBTG","BK4142","CELC","BK4139","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632593009","title":"Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632593009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632593009?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:58","pubTimestamp":1777903125,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals stock underwent a massive rally alongside a $22.5 million private placement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-cns-pharmaceuticals-stock-cnsp-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-cns-pharmaceuticals-stock-cnsp-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","BK4007","CNSP","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632958319","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2632958319","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632958319?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:52","pubTimestamp":1777895520,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals  shares were up 258% in Monday premarket activity after the company said it signed deals for a private placement financing likely to generate roughly $22.5 million.Skycorp Solar  stock was 84% higher after the company said late Friday it signed a share acquisition agreement Thursday to acquire the remaining 56% stake in Nanjing Cesun Power for about $20.2 million.Global Business Travel Group  shares were up 57% after the company's American Express Global Business Travel unit said it has agreed to be acquired by Long Lake Management in an all-cash deal valued at roughly $6.30 billion.EBay  stock was 10% higher, a day after GameStop  said it submitted a non-binding proposal to acquire all outstanding shares of eBay for $125 each.Krystal Biotech  shares were up 6.3% after the company posted higher Q1 net income and revenue.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CNSP","LU0868494617.USD","LU1623119135.USD","GBTG","LU0957808578.USD","LU1854103824.USD","BK4142","BK4588","BK4547","LU0444971666.USD","LU1854104046.USD","BK4524","LU1712237335.SGD","BK4122","LU1815336760.USD","LU1280957306.USD","KRYS","IGME","BK4096","BK4577","GME","LU1642822529.SGD","PN","LU0444973449.USD","BK4139","BK4585","LU0640476718.USD","LU0868494708.USD","LU1059921491.USD","GMEU","BK4220","EBAY","LU0942090050.USD","LU0476273544.USD","BK4007","GMEY","BK4076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632937186","title":"CNS Pharmaceuticals prices $22.5 million private placement at $2.30 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2632937186","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632937186?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:04","pubTimestamp":1777892665,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals entered securities purchase agreements for an oversubscribed private placement expected to raise about USD 22.5 million in gross proceeds.Financing includes sale of 650,000 common shares at USD 2.3 per share, pre-funded warrants to buy 9,143,479 common shares at USD 2.299 per warrant.Pre-funded warrants carry an exercise price of USD 0.001 per share; closing expected around May 5, 2026.Proceeds earmarked for acquiring clinical-stage assets with near-term catalysts, working capital, general corporate purposes; company also pursuing out-licensing of legacy Berubicin and TPI-287 programs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL1w2Jrj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530201","title":"CNS Pharmaceuticals FY25 net loss widens to $16 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530201","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530201?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:35","pubTimestamp":1774989317,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals posted a net loss of about $16 million for fiscal 2025, widening from about $15 million a year earlier.Research and development expense climbed to about $9.8 million, driven by higher spending to prepare for a TPI 287 trial including drug manufacturing, partly offset by lower Berubicin trial costs.General and administrative expense rose to about $6.2 million, mainly on higher employee compensation.Cash ended 2025 at about $7.2 million, while net cash used in operating activities narrowed to about $14 million.Management expects existing capital to fund operations into Q3 2026, while flagging need to raise significant additional capital to execute its business plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL4jhFcz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622987005","title":"CNS Pharmaceuticals Inc  expected to post a loss of $5.09 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622987005","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622987005?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:07","pubTimestamp":1774642029,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc  expected to post a loss of $5.09 a share - Earnings Preview CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to  show no change in quarterly revenue when it reports  results","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F20I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618329940","title":"CNS Pharmaceuticals launches new corporate growth strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618329940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618329940?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:52","pubTimestamp":1773233524,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The stra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-launches-new-corporate-growth-strategy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-launches-new-corporate-growth-strategy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNS","BK4135","BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618947895","title":"CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947895","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947895?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:35","pubTimestamp":1773232515,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline. CNS Pharmaceuticals Inc. announced a corporate growth strategy to build a higher-value pipeline in neurology and oncology. The company plans to conduct a global search to identify, acquire or in-license preclinical and clinical-stage assets, prioritizing programs with differentiated mechanisms, clear development and regulatory pathways, and defined value inflection points targeting unmet medical needs. CNS Pharmaceuticals also plans to prepare partnering packages to explore out-licensing its legacy assets, berubicin and TPI 287, as it shifts resources toward an acquisition-driven pipeline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL36HBpM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617693564","title":"CNS Pharmaceuticals Files Initial Beneficial Ownership Statement for CFO Steve O’Loughlin","url":"https://stock-news.laohu8.com/highlight/detail?id=2617693564","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617693564?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:00","pubTimestamp":1772661658,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. filed an initial statement of beneficial ownership naming Steve O’Loughlin, Chief Financial Officer, as the reporting person. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL2dWp7m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616337412","title":"CNS Pharmaceuticals names Lynne Kelley chief medical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337412","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616337412?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:25","pubTimestamp":1772457933,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. appointed Lynne Kelley, MD, FACS, as Chief Medical Officer, completing its executive leadership team. Kelley brings more than 20 years of experience in clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, and previously served as chief medical officer at several biotechnology and medical device companies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL6qHNLw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612452457","title":"CNS Pharmaceuticals Inc - Appoints Steve O'loughlin as CFO, Effective March 2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452457","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452457?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:37","pubTimestamp":1771335451,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0SI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612437457","title":"CNS Pharmaceuticals Sets New Executive Compensation Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2612437457","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612437457?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:36","pubTimestamp":1771335390,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has appointed Steve O'Loughlin as Chief Financial Officer effective March 2, 2026, with an initial annual base salary of $450,000 and eligibility for an annual bonus targeted at 40% of base salary, as well as annual equity grants. Christopher Downs, the current CFO, will become Senior Vice President - Finance with an annual base salary of $350,000 and a target annual bonus of 30% of base salary, along with eligibility for equity grants. Both executives are entitled to six months of base salary as severance if terminated without cause or for good reason.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electroni","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL3Nz4VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612573794","title":"CNS Pharmaceuticals Names New CEO and Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2612573794","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612573794?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:25","pubTimestamp":1771334715,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has announced new additions to its executive team, effective March 2, 2026. Rami Levin is the recently appointed President and CEO. Steven O'Loughlin will serve as Chief Financial Officer, Eric Faulkner as Chief Technology Officer, and Dylan Wenke as Chief Business Officer. These appointments are part of the company’s strategic transformation aimed at advancing its development of treatments for brain and central nervous system cancers.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL606J3c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cnspharma.com","stockEarnings":[{"period":"1week","weight":0.008},{"period":"1month","weight":1.0528},{"period":"3month","weight":0.5732},{"period":"6month","weight":-0.2681},{"period":"1year","weight":-0.6551},{"period":"ytd","weight":-0.0381}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.159728},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.133209},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.211644},{"month":4,"riseRate":0.285714,"avgChangeRate":0.005243},{"month":5,"riseRate":0.428571,"avgChangeRate":0.166259},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.175576},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.241438},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.118916},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.104014},{"month":10,"riseRate":0.166667,"avgChangeRate":0.050333},{"month":11,"riseRate":0.5,"avgChangeRate":-0.052563},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.198237}],"exchange":"NASDAQ","name":"CNS Pharmaceuticals, Inc.","nameEN":"CNS Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CNS Pharmaceuticals, Inc.,CNSP,CNS Pharmaceuticals, Inc.股票,CNS Pharmaceuticals, Inc.股票老虎,CNS Pharmaceuticals, Inc.股票老虎国际,CNS Pharmaceuticals, Inc.行情,CNS Pharmaceuticals, Inc.股票行情,CNS Pharmaceuticals, Inc.股价,CNS Pharmaceuticals, Inc.股市,CNS Pharmaceuticals, Inc.股票价格,CNS Pharmaceuticals, Inc.股票交易,CNS Pharmaceuticals, Inc.股票购买,CNS Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction